Clinical Trial

A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-06
critical Recruitment opened 2026-07-01
Trial Details
NCT Number NCT07619443
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 30 participants
Start Date 2026-07-01
Primary Completion 2026-09-05 (estimated)
Study Completion 2026-09-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-05